| Literature DB >> 26518729 |
Leilane Sales1, Julia Alejandra Pezuk2, Kleiton Silva Borges3, María Sol Brassesco4, Carlos Alberto Scrideli5, Luiz Gonzaga Tone6, Marcelo Henrique dos Santos7, Marisa Ionta8, Jaqueline Carvalho de Oliveira9.
Abstract
BACKGROUND: Glioblastoma is the most common tumor of the central nervous system and one of the hardest tumors to treat. Consequently, the search for novel therapeutic options is imperative. 7-epiclusianone, a tetraprenylated benzophenone isolated from the epicarp of the native plant Garcinia brasiliensis, exhibits a range of biological activities but its prospect anticancer activity is underexplored. Thus, the aim of the present study was to evaluate the influence of 7-epiclusianone on proliferation, clonogenic capacity, cell cycle progression and induction of apoptosis in two glioblastoma cell lines (U251MG and U138MG).Entities:
Mesh:
Substances:
Year: 2015 PMID: 26518729 PMCID: PMC4628319 DOI: 10.1186/s12906-015-0911-1
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Fig. 1Chemical structure of 7-epiclusianone
Fig. 27-epiclusianone treatments inhibit growth and clonogenic capacity. a, b Growth inhibition in U251MG and U138MG cell lines treated with 7-epiclusianone at the indicated concentrations for 48 h (MTS assay); (c-f) 7-epiclusianone potently abrogated the clonogenic capacity of both glioblastoma cell lines (*p < 0.01)
Fig. 37-epiclusianone treatments alter cell cycle progression. Cell cycle progression in U251MG (a) and U138MG (b) glioblastoma cell lines after 48 h; c Cyclin A and GAPDH expression after 48 h. *p < 0.01
Cell cycle analysis of glioblastoma cell lines after treatment with 7-epiclusianone
| U251MG | U138MG | |||
|---|---|---|---|---|
| Sub-G1 (%) | ||||
| Control | 6.35 | ±0.92 | 6.45 | ±3.68 |
| 10 μM | 5.92 | ±3.00 | 13.98 | ±6.14 |
| 20 μM | 7.80 | ±1.00 | 12.99 | ±0.81 |
| 30 μM | 9.88 | ±1.09 | 15.66 | ±2.82 |
| 40 μM | 14.74 | ±0.94* | 22.50 | ±2.45* |
| G1 (%) | ||||
| Control | 54.97 | ±2.76 | 65.54 | ±3.86 |
| 10 μM | 68.94 | ±2.34* | 65.70 | ±4.20 |
| 20 μM | 59.67 | ±3.82 | 55.99 | ±0.54* |
| 30 μM | 57.02 | ±2.97 | 54.92 | ±0.68* |
| 40 μM | 45.77 | ±1.49* | 50.72 | ±2.58* |
| S (%) | ||||
| Control | 5.07 | ±1.07 | 6.83 | ±0.73 |
| 10 μM | 3.59 | ±1.63 | 4.32 | ±0.76* |
| 20 μM | 6.77 | ±0.41 | 7.44 | ±0.75 |
| 30 μM | 6.93 | ±0.39 | 7.45 | ±0.92 |
| 40 μM | 6.23 | ±1.92 | 4.74 | ±0.17* |
| G2/M (%) | ||||
| Control | 33.79 | ±2.34 | 21.24 | ±0.50 |
| 10 μM | 21.36 | ±1.05* | 17.25 | ±3.05* |
| 20 μM | 25.44 | ±2.99* | 23.51 | ±0.90 |
| 30 μM | 26.10 | ±1.66* | 22.32 | ±3.65 |
| 40 μM | 33.62 | ±2.28 | 21.99 | ±1.92 |
Percentages of cells in Sub-G1, G1, S and G2/M phases are expressed as mean ± standard deviation
*p < 0.05
Fig. 47-epiclusianone treatments alter apoptotic rates. a, c-f Increased Annexin V positive cells after treatment with 7-epi-clusianone in glioblastoma (GBM) cells lines; b Increased caspase-3 activation rates after treatment with 7-epiclusianone in GBM cells lines (data are expressed as the mean-SD of all cell lines). *p < 0.05, **p < 0.01. PI, propidium iodide